Cargando…

Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus

Background  Kaposiform hemangioendothelioma (KHE) is a vascular tumor frequently associated with Kasabach–Merritt phenomenon (KMP), characterized by severe thrombocytopenia and consumptive coagulopathy. Visceral involvement in KHE is rare. In our recent experience, sirolimus has shown to be an effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Triana, Paloma Junco, Dore, Mariela, Nuñez, Vanesa Cerezo, Jimenez, Javier Gomez, Miguel, Miriam Ferrero, Díaz, Mercedes González, Ricardo, Joan Novo, Andres, Ane, Lopez Santamaria, Manuel, Lopez-Gutierrez, Juan Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Georg Thieme Verlag KG 2017
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533608/
https://www.ncbi.nlm.nih.gov/pubmed/28761800
http://dx.doi.org/10.1055/s-0037-1604358
_version_ 1783253646584053760
author Triana, Paloma Junco
Dore, Mariela
Nuñez, Vanesa Cerezo
Jimenez, Javier Gomez
Miguel, Miriam Ferrero
Díaz, Mercedes González
Ricardo, Joan Novo
Andres, Ane
Lopez Santamaria, Manuel
Lopez-Gutierrez, Juan Carlos
author_facet Triana, Paloma Junco
Dore, Mariela
Nuñez, Vanesa Cerezo
Jimenez, Javier Gomez
Miguel, Miriam Ferrero
Díaz, Mercedes González
Ricardo, Joan Novo
Andres, Ane
Lopez Santamaria, Manuel
Lopez-Gutierrez, Juan Carlos
author_sort Triana, Paloma Junco
collection PubMed
description Background  Kaposiform hemangioendothelioma (KHE) is a vascular tumor frequently associated with Kasabach–Merritt phenomenon (KMP), characterized by severe thrombocytopenia and consumptive coagulopathy. Visceral involvement in KHE is rare. In our recent experience, sirolimus has shown to be an effective treatment in cutaneous KHE, becoming indeed the treatment of choice in KMP. We report a case of pancreatic KHE associated with KMP and refractory to sirolimus. Case Report  A 4-month-old infant is referred for obstructive jaundice (10 mg/dL conjugated bilirubin) secondary to vascular pancreatic tumor. Magnetic resonance (MR) and immunohistochemistry were compatible with KHE, but the tumor was considered unresectable. We initiated sirolimus (0.8 mg/m (2) /12 h) to treat KMP, and interventional radiology was performed for percutaneous biliary diversion. This procedure prompted KMP (platelets: 51,000/µL). Sirolimus treatment for 7 days showed no effect; therefore, we started our VAT protocol (vincristine/aspirine/ticlopidin) with great response after 10 days (platelets: 3,70,000/µL). Three months later, percutaneous biliary diversion was replaced by a biliary stent. The tumor disappeared leaving fibrosis and dilatation of biliary tract needing hepaticojejunostomy 6 months later. Discussion  It is difficult to establish protocols for an unusual presentation of a tumor with different targets. This is a reason collaborative multicenter studies should be performed. Management of obstructive jaundice secondary to a tumor that usually regresses in 10 years is an added challenge; therefore, the management should be led by a multidisciplinary team. Sirolimus treatment in cutaneous KHE has been described as successful in the literature, as well as in our own experience; however, it failed in our first patient with visceral KHE. We need to investigate the different response to pharmacological agents in tumors with similar histopathology, but with visceral involvement.
format Online
Article
Text
id pubmed-5533608
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Georg Thieme Verlag KG
record_format MEDLINE/PubMed
spelling pubmed-55336082017-07-31 Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus Triana, Paloma Junco Dore, Mariela Nuñez, Vanesa Cerezo Jimenez, Javier Gomez Miguel, Miriam Ferrero Díaz, Mercedes González Ricardo, Joan Novo Andres, Ane Lopez Santamaria, Manuel Lopez-Gutierrez, Juan Carlos European J Pediatr Surg Rep Background  Kaposiform hemangioendothelioma (KHE) is a vascular tumor frequently associated with Kasabach–Merritt phenomenon (KMP), characterized by severe thrombocytopenia and consumptive coagulopathy. Visceral involvement in KHE is rare. In our recent experience, sirolimus has shown to be an effective treatment in cutaneous KHE, becoming indeed the treatment of choice in KMP. We report a case of pancreatic KHE associated with KMP and refractory to sirolimus. Case Report  A 4-month-old infant is referred for obstructive jaundice (10 mg/dL conjugated bilirubin) secondary to vascular pancreatic tumor. Magnetic resonance (MR) and immunohistochemistry were compatible with KHE, but the tumor was considered unresectable. We initiated sirolimus (0.8 mg/m (2) /12 h) to treat KMP, and interventional radiology was performed for percutaneous biliary diversion. This procedure prompted KMP (platelets: 51,000/µL). Sirolimus treatment for 7 days showed no effect; therefore, we started our VAT protocol (vincristine/aspirine/ticlopidin) with great response after 10 days (platelets: 3,70,000/µL). Three months later, percutaneous biliary diversion was replaced by a biliary stent. The tumor disappeared leaving fibrosis and dilatation of biliary tract needing hepaticojejunostomy 6 months later. Discussion  It is difficult to establish protocols for an unusual presentation of a tumor with different targets. This is a reason collaborative multicenter studies should be performed. Management of obstructive jaundice secondary to a tumor that usually regresses in 10 years is an added challenge; therefore, the management should be led by a multidisciplinary team. Sirolimus treatment in cutaneous KHE has been described as successful in the literature, as well as in our own experience; however, it failed in our first patient with visceral KHE. We need to investigate the different response to pharmacological agents in tumors with similar histopathology, but with visceral involvement. Georg Thieme Verlag KG 2017-01 2017-07-28 /pmc/articles/PMC5533608/ /pubmed/28761800 http://dx.doi.org/10.1055/s-0037-1604358 Text en © Thieme Medical Publishers
spellingShingle Triana, Paloma Junco
Dore, Mariela
Nuñez, Vanesa Cerezo
Jimenez, Javier Gomez
Miguel, Miriam Ferrero
Díaz, Mercedes González
Ricardo, Joan Novo
Andres, Ane
Lopez Santamaria, Manuel
Lopez-Gutierrez, Juan Carlos
Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
title Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
title_full Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
title_fullStr Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
title_full_unstemmed Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
title_short Pancreatic Kaposiform Hemangioendothelioma Not Responding to Sirolimus
title_sort pancreatic kaposiform hemangioendothelioma not responding to sirolimus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5533608/
https://www.ncbi.nlm.nih.gov/pubmed/28761800
http://dx.doi.org/10.1055/s-0037-1604358
work_keys_str_mv AT trianapalomajunco pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT doremariela pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT nunezvanesacerezo pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT jimenezjaviergomez pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT miguelmiriamferrero pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT diazmercedesgonzalez pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT ricardojoannovo pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT andresane pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT lopezsantamariamanuel pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus
AT lopezgutierrezjuancarlos pancreatickaposiformhemangioendotheliomanotrespondingtosirolimus